{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:48:07Z","timestamp":1777855687254,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Mens Health"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>While prostate-specific antigen (PSA) testing can reduce mortality, there is potential for over-detection of indolent prostate cancer that would never become clinically important. Thus, research is needed to understand individual genetic risk profiles among unaffected men to help guide personalized PSA screening. This pilot study explored recruitment outcomes, genetic risk perceptions, and willingness to provide a biospecimen (saliva sample) for prostate cancer genetic risk testing among unaffected men. Recruitment approaches included: (1) active (in-person) recruitment that entailed face-to-face communications with men at different community settings, such as health fairs, senior centers, and barbershops and (2) passive (contactless) recruitment\u2014flyers posted at various community locations, such as libraries and laundromats, and online including Facebook pages and other social media. Consenting participants completed a structured questionnaire and provided a saliva sample. A total of 154 individuals were reached and 100 consented (62 of whom were Black). In-person recruitment was associated with higher enrollment. Participants reported high genetic susceptibility beliefs in terms of perceived lifetime risk and comparative risk. Black males reported greater perceived risk compared with white men, but saliva sample return was comparable (89% and 90%, respectively). Overall, the saliva sample return rate was 85%, with an in-person return rate of 95%, and a mail return rate of 69%. This pilot study demonstrated high feasibility of enrollment, high perceived genetic risk and willingness to submit a saliva sample for prostate cancer genetic risk testing. Multimodal approaches are beneficial to reach racially diverse participants in various community settings.<\/jats:p>","DOI":"10.1177\/15579883251410526","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:37:32Z","timestamp":1767919052000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of Recruitment, Perceived Genetic Risk and Susceptibility Beliefs, and Saliva Sample Collection in a Community-Based Prostate Cancer Genetic Risk Pilot Study"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4106-7092","authenticated-orcid":false,"given":"Carol","family":"Boxtha","sequence":"first","affiliation":[{"name":"Department of Non-Therapeutic Research Office, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8770-948X","authenticated-orcid":false,"given":"Samaa","family":"El-Kolalli","sequence":"additional","affiliation":[{"name":"Department of Non-Therapeutic Research Office, Moffitt Cancer Center, Tampa, FL, USA"},{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7584-6510","authenticated-orcid":false,"given":"Justin","family":"Denis","sequence":"additional","affiliation":[{"name":"Department of Non-Therapeutic Research Office, Moffitt Cancer Center, Tampa, FL, USA"},{"name":"College of Arts and Sciences, University of South Florida, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2899-6369","authenticated-orcid":false,"given":"Ashley","family":"O\u2019Neil","sequence":"additional","affiliation":[{"name":"Department of Non-Therapeutic Research Office, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-6917","authenticated-orcid":false,"given":"Susan T.","family":"Vadaparampil","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA"},{"name":"Office of Community Outreach, Engagement, and Equity, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7414-7246","authenticated-orcid":false,"given":"Rania","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Department of Non-Therapeutic Research Office, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6384-6447","authenticated-orcid":false,"given":"Jong Y.","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1630-7333","authenticated-orcid":false,"given":"Clement K.","family":"Gwede","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL, USA"},{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"American Cancer Society. (2023). American Cancer Society recommendations for prostate cancer early detection. https:\/\/www.cancer.org\/health-care-professionals\/american-cancer-society-prevention-early-detection-guidelines\/prostate-cancer-screening-guidelines.html"},{"key":"e_1_3_3_3_1","unstructured":"American Cancer Society. (2024). Cancer facts & figures 2024. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2024-cancer-facts-figures.html"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Andrykowski M. A. Burris J. L. Walsh E. Small B. J. Jacobsen P. B. (2010). Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: Breast cancer survivors compared with healthy controls. Journal of Clinical Oncology 28(21) 3442\u20133447. https:\/\/doi.org\/10.1200\/JCO.2009.27.8267","DOI":"10.1200\/JCO.2009.27.8267"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Baptista P. V. (2005). Principles in genetic risk assessment. Therapeutics and Clinical Risk Management 1(1) 15\u201320. https:\/\/doi.org\/10.2147\/tcrm.1.1.15.53606","DOI":"10.2147\/tcrm.1.1.15.53606"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Bergengren O. Pekala K. R. Matsoukas K. Fainberg J. Mungovan S. F. Bratt O. Bray F. Brawley O. Luckenbaugh A. N. Mucci L. Morgan T. M. Carlsson S. V. (2023). 2022 update on prostate cancer epidemiology and risk factors-A systematic review. European Urology 84(2) 191\u2013206. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.021","DOI":"10.1016\/j.eururo.2023.04.021"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Connor J. Kyalwazi A. Turkson-Ocran R. A. Olveczky D. (2022). Promoting inclusive recruitment: A qualitative study of Black adults\u2019 decision to participate in genetic research. Journal of Urban Health 99(5) 803\u2013812. https:\/\/doi.org\/10.1007\/s11524-022-00664-0","DOI":"10.1007\/s11524-022-00664-0"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Conti D. V. Darst B. F. Moss L. C. Saunders E. J. Sheng X. Chou A. Schumacher F. R. Olama A. A. A. Benlloch S. Dadaev T. Brook M. N. Sahimi A. Hoffmann T. J. Takahashi A. Matsuda K. Momozawa Y. Fujita M. Muir K. Lophatananon A. . . .Haiman C. A. (2021). Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics 53(1) 65\u201375. https:\/\/doi.org\/10.1038\/s41588-020-00748-0","DOI":"10.1038\/s41588-020-00748-0"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Davis S. N. Govindaraju S. Jackson B. Williams K. R. Christy S. M. Vadaparampil S. T. Quinn G. P. Shibata D. Roetzheim R. Meade C. D. Gwede C. K. (2018). Recruitment techniques and strategies in a community-based colorectal cancer screening study of men and women of African ancestry. Nursing Research 67(3) 212\u2013221. https:\/\/doi.org\/10.1097\/NNR.0000000000000274","DOI":"10.1097\/NNR.0000000000000274"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Davis S. N. Sutton S. K. Vadaparampil S. T. Meade C. D. Rivers B. M. Patel M. V. Torres-Roca J. F. Heysek R. V. Spiess P. Pow-Sang J. Jacobsen P. B. Gwede C. K. (2014). Informed decision making among first-degree relatives of prostate cancer survivors: A pilot randomized trial. Contemporary Clinical Trials 39(2) 327\u2013334. https:\/\/doi.org\/10.1016\/j.cct.2014.10.007","DOI":"10.1016\/j.cct.2014.10.007"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Georgiou L. A. Scarbrough B. E. (2024). PSA screening for prostate cancer in the United States: 30 years of controversy. Journal of Public Health Policy 45(3) 552\u2013561. https:\/\/doi.org\/10.1057\/s41271-024-00502-4","DOI":"10.1057\/s41271-024-00502-4"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Gwede C. K. Davis S. N. Wilson S. Patel M. Vadaparampil S. T. Meade C. D. Rivers B. M. Yu D. Torres-Roca J. Heysek R. Spiess P. E. Pow-Sang J. Jacobsen P. (2015). Perceptions of prostate cancer screening controversy and informed decision making: Implications for development of a targeted decision aid for unaffected male first-degree relatives. American Journal of Health Promotion 29(6) 393\u2013401. https:\/\/doi.org\/10.4278\/ajhp.130904-QUAL-463","DOI":"10.4278\/ajhp.130904-QUAL-463"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Harvey K. Ralph P. Spencer L. H. Doungsong K. Morrison V. Lemmey A. Golding-Day M. Dodd S. Hardwick B. Dorkenoo S. Hennessey S. Williams N. (2024). Perceived barriers and facilitators of staff recruiting participants to a randomised controlled trial of a community rehabilitation intervention following hip fracture. Trials 25(1) 826. https:\/\/doi.org\/10.1186\/s13063-024-08655-z","DOI":"10.1186\/s13063-024-08655-z"},{"key":"e_1_3_3_14_1","doi-asserted-by":"crossref","unstructured":"Jackson S. D. de la Rue M. R. Greenslade T. P. John A. M. Wahid S. Martin R. M. Williams N. J. Turner E. L. (2022). Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testing. Journal of Medical Screening 29(4) 268\u2013271. https:\/\/doi.org\/10.1177\/09691413221119238","DOI":"10.1177\/09691413221119238"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Lowder D. Rizwan K. McColl C. Paparella A. Ittmann M. Mitsiades N. Kaochar S. (2022). Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Letters 531 71\u201382. https:\/\/doi.org\/10.1016\/j.canlet.2022.01.028","DOI":"10.1016\/j.canlet.2022.01.028"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Martin R. M. Turner E. L. Young G. J. Metcalfe C. Walsh E. I. Lane J. A. Sterne J. A. C. Noble S. Holding P. Ben-Shlomo Y. Williams N. J. Pashayan N. Bui M. N. Albertsen P. C. Seibert T. M. Zietman A. L. Oxley J. Adolfsson J. Mason M. D. . . . CAP Trial Group. (2024). Prostate-specific antigen screening and 15-year prostate cancer mortality: A secondary analysis of the CAP randomized clinical trial. Journal of the American Medical Association 331(17) 1460\u20131470. https:\/\/doi.org\/10.1001\/jama.2024.4011","DOI":"10.1001\/jama.2024.4011"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Moyer V. A. Force U. S. P. S. T. (2012). Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 157(7) 512\u2013518. https:\/\/doi.org\/10.7326\/0003-4819-157-7-201210020-00514","DOI":"10.7326\/0003-4819-157-7-201210020-00514"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Pepe P. Pennisi M. (2022). Morbidity following transperineal prostate biopsy: Our experience in 8.500 men. Archivio Italiano di Urologia e Andrologia 94(2) 155\u2013159. https:\/\/doi.org\/10.4081\/aiua.2022.2.155","DOI":"10.4081\/aiua.2022.2.155"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Peshkin B. N. Ladd M. K. Isaacs C. Segal H. Jacobs A. Taylor K. L. Graves K. D. O\u2019Neill S. C. Schwartz M. D. (2021). The Genetic Education for Men (GEM) Trial: Development of web-based education for untested men in BRCA1\/2-positive families. Journal of Cancer Education 36(1) 72\u201384. https:\/\/doi.org\/10.1007\/s13187-019-01599-y","DOI":"10.1007\/s13187-019-01599-y"},{"key":"e_1_3_3_20_1","doi-asserted-by":"crossref","unstructured":"Pinsky P. F. Miller E. Prorok P. Grubb R. Crawford E. D. Andriole G. (2019). Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate Lung Colorectal and Ovarian randomized cancer screening trial. BJU International 123(5) 854\u2013860. https:\/\/doi.org\/10.1111\/bju.14580","DOI":"10.1111\/bju.14580"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Raychaudhuri R. Lin D. W. Montgomery R. B. (2025). Prostate cancer: A review. Journal of the American Medical Association 333(16) 1433\u20131446. https:\/\/doi.org\/10.1001\/jama.2025.0228","DOI":"10.1001\/jama.2025.0228"},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Roy S. Gwede C. K. Malo T. L. Scherr C. L. Radlein S. Meade C. D. Vadaparampil S. T. Park J. Y. (2020). Exploring prostate cancer patients\u2019 interest and preferences for receiving genetic risk information about cancer aggressiveness. American Journal of Men\u2019s Health 14(3) 1557988320919626. https:\/\/doi.org\/10.1177\/1557988320919626","DOI":"10.1177\/1557988320919626"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Seibert T. M. Garraway I. P. Plym A. Mahal B. A. Giri V. Jacobs M. F. Cheng H. H. Loeb S. Helfand B. T. Eeles R. A. Morgan T. M. (2023). Genetic risk prediction for prostate cancer: Implications for early detection and prevention. European Urology 83(3) 241\u2013248. https:\/\/doi.org\/10.1016\/j.eururo.2022.12.021","DOI":"10.1016\/j.eururo.2022.12.021"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Van Poppel H. Albreht T. Basu P. Hogenhout R. Collen S. Roobol M. (2022). Serum PSA-based early detection of prostate cancer in Europe and globally: Past present and future. Nature Reviews Urology 19(9) 562\u2013572. https:\/\/doi.org\/10.1038\/s41585-022-00638-6","DOI":"10.1038\/s41585-022-00638-6"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Vickers A. O\u2019Brien F. Montorsi F. Galvin D. Bratt O. Carlsson S. Catto J. W. Krilaviciute A. Philbin M. Albers P. (2023). Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. The BMJ 381 Article e071082. https:\/\/doi.org\/10.1136\/bmj-2022-071082","DOI":"10.1136\/bmj-2022-071082"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Wang X. Cheng Z. (2020). Cross-sectional studies: Strengths weaknesses and recommendations. Chest 158(Suppl. 1) S65\u2013S71. https:\/\/doi.org\/10.1016\/j.chest.20-20.03.012","DOI":"10.1016\/j.chest.2020.03.012"}],"container-title":["American Journal of Men's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883251410526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15579883251410526","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15579883251410526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:28:32Z","timestamp":1777505312000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15579883251410526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/15579883251410526"],"URL":"https:\/\/doi.org\/10.1177\/15579883251410526","relation":{},"ISSN":["1557-9883","1557-9891"],"issn-type":[{"value":"1557-9883","type":"print"},{"value":"1557-9891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"15579883251410526"}}